EDITORIALS

Recognition for Canadian Scientists
This issue features the R.O. Jones Founding President Lecture delivered by Dr. John Morihisa at the Vancouver Annual Meeting in 1986. The lecture illustrates how fundamental neuroscience is generating new knowledge which can now be applied to clinical problems in psychiatry.
I wish to draw attention to contributions of some Canadian scientists to the areas Morihisa discusses, that is, frontal lobe dysfunction and brain tissue grafting.
There are two reasons for this Canadian emphasis. First, there is a long lag-time, often twenty years or more, between the time a basic contribution is made and its clinical application. Thus, contemporary clinicians may well be unaware of the origin of current findings. The second reason is particular to Canadians. We hide our lights under bushels. Our preoccupation with fairness stops our stars from rising. We are restrained in giving recognition to scientists by injunctions of the Canadian conscience which requires regional equality and equal access to everything. The development of scientists is not favoured by these values. Scientists are developed by those who place a higher value on quality than equality, by those who promote excellent students and who give them encouragement and resources preferentially over those whose talents lie in other areas.
Morihisa summarizes fascinating new information about the frontal lobes and schizophrenia. The slow process of solving the riddles of the frontal lobes was accelerated at McGill in 1963 when Brenda Milner (1) observed that the frontal lobes have a special role in solving problems, in spite of their remote relation to measured intelligence. Frontal lobe lesioned patients were unable to inhibit an unwanted response, even though aware the response was undesirable. Thus, they failed to link the intention to perform an act with its execution. Milner has gone on to make numerous contributions to our understanding of the frontal lobes. Canadian contributions to this field in the future are assured by the energy and expertise of Donald Stuss (2), of the University of Ottawa.
The idea that brain tissue grafts might be used as sources of dopamine in the treatment of Parkinson's disease would have seemed outlandish in 1966 when Hornykiewicz (3) revealed the function of striatal dopamine. He later extended his work at the University of Toronto. Brain tissue grafts have created such excitement that they have been hastily inserted in some 333 patients. It is unfortunate that treatment failures and possibly damaging effects could discredit this approach. Fortunately, meticulous and systematic work on the kind of tissues required, the endurance of the graft, and its efficacy at repairing damaged motor and cognitive programs, is being systematically studied by Michele Pisa (4) and colleagues at McMaster University.
These examples illustrate that we have had and continue to have fine neuroscientists in this country. The relevance of their contributions to clinical psychiatry is only now becoming clear. Information about the new developments are accessible to psychiatrists through the meetings of the Canadian College of Neuropsychopharmacology where both clinical and basic scientists meet.
Canada has many fine neuroscientists. However, we need more clinical scientists to examine the implications of basic research in the neurosciences. We must strengthen our training in clinical investigation and encourage the most able students to pursue careers in research. This will require a discriminating and a seemingly unfair allocation of funds, and a willingness to give such people recognition, if we are to grasp the opportunity to improve our understanding and treatment of the dreadful disorders we confront every day.
The antipsychotic and antidepressant drugs were discovered 35 years ago as a result of observations and good luck. We have entered a new era in which specific brain mechanisms can be identified and precise treatment interventions can be postulated logically, and tested.
